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Abstract
Endothelin-1 (ET-1), the predominant isoform of the ET peptide family and a potent vasoconstrictor, has been shown to aggravate
ischemia-induced ventricular arrhythmias. However, there is also evidence that ET-1 may have a direct arrhythmogenic action that is not
solely attributable to myocardial ischemia. Proposed mechanisms for the arrhythmogenic effects of ET-1 are prolongation or increased
dispersion of monophasic action potential duration, QT prolongation, development of early afterdepolarizations, acidosis, and
21
augmentation of cellular injury. As for an ionic basis for the observed electrophysiologic effects, ET-induced Ca release from
1 1 1intracellular stores, generation of inositol triphosphate, inhibition of delayed rectifier K current, and stimulation of the Na /H
exchanger may be involved. Recently, some studies have shown that ET receptor antagonists, which promise to be powerful tools in
cardiovascular medicine, may also demonstrate antiarrhythmic properties. This review describes the current state of knowledge on the
interactions between the ET system and cardiac arrhythmias, and discusses the therapeutic potential of ET antagonists as antiarrhythmic
drugs. Ó 2001 Elsevier Science B.V. All rights reserved.
Keywords: Antiarrhythmic agents; Arrhythmia (mechanisms); Endothelins
1. Introduction 2. Endothelin: an endogenous peptide
There is an accumulating body of evidence suggesting The vascular endothelium regulates vascular tone and
that endothelin-1 (ET-1), the predominant isoform of the cell proliferation through release of vasoactive factors,
21-amino acid ET peptide family and a potent vasocon- growth factors, and controls blood coagulation and platelet
strictor, also has arrhythmogenic effects [1–11]. Recently, aggregation [15]. Soon after the discovery of endothelium-
a small number of animal studies have shown that ET derived relaxing factor [16], it became clear that the
antagonists, which compete for binding sites for ET-1, may endothelium is also a source of vasoconstrictor substances.
demonstrate antiarrhythmic properties [12–14]. This article Originally described as an endothelium-derived vasocon-
aims to provide a review of the current state of knowledge stricting factor released upon stimulation with vasoactive
on the proarrhythmic effects of ET-1 as well as the agonists [17], it was named endothelin thereafter [18]. The
therapeutic potential of ET antagonists as antiarrhythmic discovery of this peptide initiated a new field of bio-
drugs. medical research leading to better understanding of the
pathogenesis of numerous disease states and to the de-
velopment of novel therapeutics. In the cardiovascular
system, ET-1 is an extremely potent vasoconstrictor and
stimulates cell proliferation in an autocrine fashion in
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muscle and mesangial cells, and cardiac myocytes [19,20]. amino-acid peptides including ET-2 and ET-3 which show
ET-1 has recently been identified to play an important role different profiles of activity in various tissues [27,28]. Both
for vascular remodeling and function in hypertension and ET-1 and ET-3 (which differs from ET-1 by six amino
atherosclerosis [21,22]. Interactions between ET-1, vasoac- acids) are vasoactive peptides, although ET-1 is more than
tive mediators, blood cells, and the arterial vessel wall are 100-fold more potent than ET-3 as a vasoconstrictor. ET
shown in Fig. 1. receptors consist of ET and ET subtypes in mammalsA B
[28]. The ET subtype accounts for more than 90% of ETA
2.1. Regulation of endothelin synthesis receptors in isolated myocytes [29]. In addition, ETA
receptors predominate in the tunica media of intramyocar-
Transcription of the preproET-1 gene leads to pro- dial vessels [30,31]. ET receptors are localized to otherB
duction of prepro-ET-1, a 203-amino-acid peptide, which cell types, such as endothelial cells, and neuronal tissue
is cleaved by specific peptidases to the inactive 38-amino and fibroblasts [32,33]. Although ET receptors are theA
acid precursor big ET-1 [18]. Big ET-1 is further processed predominant subtype in the vasculature, in other human
to ET-1 by several endothelin converting enzymes (ECE) tissues such as the kidney receptors are more abundant
[23,24]. ET-1 gene transcription is regulated by growth [34]. In the vasculature, the ET subtype is being exclu-A
factors, such as TNFa, TGFb-1 and bFGF-2, in an sively expressed on vascular smooth muscle cells, whereas
autocrine manner [19]. Although plasma levels of ET-1 are ET receptors are localized on both endothelial cells andB
rather low and may only reflect a fraction of actual — to a lesser extent — on certain vascular smooth muscle
production in the tissue, in numerous cardiovascular cells [35]. The ET receptor shows greater selectivity forA
disorders associated with arrhythmias including athero- ET-1 and ET-2 than for ET-3, while the three isopeptides
sclerosis, acute myocardial infarction, and congestive heart are equipotent at the ET receptor. Stimulation of ETB A
failure, circulating levels of ET-1 are increased suggesting receptors causes contraction, proliferation and migration,
activation of the ET system [25,26]. whereas stimulation of ET receptors increases NO releaseB
and relaxation. Recent studies have shown that in the
2.2. Endothelin isoforms and receptors failing and non-failing human heart, ET and ET re-A B
ceptors coexist; however, ET receptors appear to beA
ET-1 is the predominant isoform of a group of three 21 functionally relevant [36—38].
Fig. 1. Interactions between endothelin-1, vasoactive mediators, blood cells, and the arterial vessel wall: ET-1 is generated within endothelial and vascular
smooth muscle cells in response to stimuli, such as angiotensin II, thrombin, decreased pH, and also by autocrine stimulation through ET-1. Stimulation of
endothelial ET receptors stimulates release of NO and adrenomedullin as well as vasorelaxation, whereas ET receptors activate contraction, cellB A
proliferation, and migration. ET-1 stimulates interleukin expression in monocytes, and increases platelet aggregation. In addition, ET-1 stimulates the
production and potentiates the action of several growth factors, increases DNA and protein synthesis, and promotes cell cycle progression. (Ang II,
2
angiotensin II; ANP, atrial natriuretic peptide; ONOO , peroxynitrite; ECE, endothelin converting enzyme; ET-1, endothelin-1; ET , endothelin subtype AA
. 2
receptor, ET , endothelin subtype B receptor; NO, nitric oxide; NOS, nitric oxide synthase; O , superoxide anion; IL-1, interleukin 1; IL-6, interleukin 2,B 2
IL-8, interleukin 8; TGF-b1, transforming growth factor b1; bFGF-2, basic fibroblast growth factor-2; NADPHox, NADPH oxidase; PDGF, platelet-
¨derived growth factor; VEGF, vascular endothelial growth factor; 1, stimulation, 2, inhibition.) (Reproduced from Ref. [28] Barton M, Luscher TF.
Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens 1999;8:549–555, with permission).
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2.3. Endothelin antagonists the binding profile of ET receptors. In contrast, the ETA B
receptor antagonist, BQ-788, has a low, micromolar affini-
Discovery of the ET receptors has enabled the develop- ty and shows no significant binding in human left ventricu-
ment of specific receptor antagonists. These agents can be lar tissue. Cardiovascular ET receptors from human tissueB
divided into receptor-selective (ET or ET ) or unselective may differ from those in other vascular beds from otherA B
(blockade of both receptors) compounds. Several peptides species since the binding profile for ET selective ligandsB
or non-peptide compounds are now available and some are differed markedly for human tissue and rat and porcine
in clinical development (Table 1). Some of these com- heart tissue. These results suggest that extrapolating from
pounds are peptides prohibiting oral application but orally data derived from animal studies to human studies appears
active compounds have recently become available, some of to be more reliable for ET receptors as compared to ETA B
which are already evaluated in clinical studies (e.g. bosen- receptors, yielding important implications for pharmaco-
Òtan tracleer , a non-selective receptor antagonist) [39]. logical inhibition of the receptors.
The cyclic pentapeptide ET antagonist, BQ-123, has been
utilized in numerous studies investigating its non-car-
diovascular [40,41] and cardiovascular effects [42–46]. 3. Arrhythmogenic effects of endothelin
Studies using ligand binding techniques to determine the
affinity and selectivity of ET receptor agonists and antago- 3.1. Ischemia-induced effects of exogenous endothelin
nists in human left ventricle which expresses both ET andA
ET receptors showed that the ET antagonists BQ-123 and Because of its vasoconstrictor potency, exogenouslyB
FR139317 are highly selective for the ET subtype with administered ET-1 may induce arrhythmias associated withA
similar sub-nanomolar affinities as the endogenous agonist myocardial ischemia. Lethal ventricular arrhythmias were
ligand ET-1 [46]. No species differences were detected in reported in studies of perfused pig hearts, caused by a
Table 1
aSome of the endothelin receptor antagonists currently under evaluation in preclinical studies and clinical trials
bCompound Target Company Indication /comments
A-127772 ET AbbottA
A-182086 ET /ET AbbottA B
ABT-627 ET Abbott CHF, prostate cancerA
BMS-182874 ET Bristol Myers Squibb CHFA
BQ-123 ET Banyu I.v. use onlyA
BQ-485 ET Banyu I.v. use onlyA
CGS-27830 ET /ET NovartisA B
FR-139317 ET Fujisawa Pharm.A
L-749329 ET MerckA
L-753037 ET /ET MerckA B
LU135252 (darusentan) ET Knoll CHF, hypertensionA
LU208075 ET Knoll CHF, hypertensionA
LU302146 ET Knoll Occlusive vascular diseaseA
LU224332 ET /ET KnollA B
PD-142893 ET /ET Parke-Davis Cardiovascular diseasesA B
PD-147953 ET Parke-Davis Cardiovascular diseasesA
PD-151242 ET Parke-Davis Cardiovascular diseasesA
PD-155080 ET Parke-Davis Cardiovascular diseasesA
RO 47-0203 (3 basentan) ET /ET Hoffmann-La Roche Heart failure, hypertensionA B
RO 48-5695 ET /ET Hoffmann-La RocheA B
RO 61-1790 ET Hoffmann-La Roche SAH; i.v. use onlyA
SB-209670 ET /ET SmithKline Beecham Cardiovascular indications,A B
radiocontrast nephropathy
SB-247083 ET SmithKline BeechamA
TAK-044 ET /ET ET Parke-Davis CAD, SAH, renal transplantA A B
rejection; i.v. use only
TBC11251 Texas Biotechnology CHF, primary pulmonary
hypertension
ZD 1611 ET Zeneca Obstructive lung disease,A
primary pulmonary hypertension
a Compounds listed are either selective for the ET receptor or combined ET /ET receptor antagonists. Clinical information is noted if information wasA A B
available. Some of the drugs are only suited for intravenous use due to their peptide structure.
b CHF, chronic heart failure; CAD, coronary artery disease; SAH, subarachnoidal hemorrhage.
¨(Modified from Ref. [28]; Barton M, Luscher TF. Endothelin antagonists for hypertension and renal disease. Curr Opin Nephrol Hypertens
1999;8:549–555.)
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progressive decline in coronary flow [47]. Salvati et al. attributable to myocardial ischemia [1–3]. When ET-1 was
demonstrated that the occurrence of arrhythmias always administered into the coronary ostia in anesthetized rats,
paralleled ECG changes typical of myocardial ischemia ventricular arrhythmias developed at doses above 0.5 mg/
and a decrease in coronary blood flow in open-chest kg and were precipitated into ventricular fibrillation at 1
anesthetized dogs [4]. When infused into the left circum- mg/kg. At the time when the arrhythmias developed, the
flex artery, ET-1 caused ventricular tachycardia degenerat- ischemic changes had already subsided, supporting the
ing into ventricular fibrillation at 80 pmol /kg, but fatal hypothesis that ET-1 might exert primary proarrhythmic
arrhythmias occurred already at lower doses (20 pmol /kg) effects. Recently, Szabo et al. compared the effects of total
during infusion into the left anterior descending artery. occlusion of left anterior descending artery (group A) to
Garjani et al. assessed the effects of intravenous infusions intracoronary administration of ET-1 (at a rate of 30
of exogenous ET-1 on incidence and severity of ventricular pmol /min, group B; and 60 pmol /min, group C) in open-
arrhythmias during acute myocardial ischemia in anes- chest mongrel dogs [54]. Blood samples for lactate mea-
thetized rats [12]. Exogenous ET-1 (at doses of 0.05 and surements were collected from the coronary sinus (CS) and
0.1 nmol /kg/min) increased the severity and incidence of infrared imaging was applied to follow epimyocardial heat
ischemic arrhythmias dose-dependently. Both doses in- emission images. The investigators demonstrated that ET-
creased the total incidence of ventricular ectopic beats, 1-induced arrhythmias occurred without any ischemic
whereas the higher dose also increased the total duration of thermographic changes or elevations in CS lactate levels in
ventricular tachycardia. Other investigators observed ven- group B and without CS lactate elevations in group C,
tricular arrhythmias accompanying a moderate reduction in whereas both parameters were significantly changed in
coronary blood flow [5] [8]. Intrapericardial infusion of group A. In a similar comparison study, Becker et al.
ET-1 in dogs was shown to cause ischemic changes and analyzed three-dimensional activation patterns of ventricu-
induce monomorphic and polymorphic ventricular tachy- lar arrhythmias induced by intracoronary administration of
cardia which spontaneously disappeared or degenerated ET-1 in comparison with arrhythmias induced by ligation
into ventricular fibrillation [7]. of the left anterior descending artery in foxhounds [55].
The cellular mechanisms of reperfusion-induced arrhyth- The investigators demonstrated marked differences in
mias are likely to differ from those responsible for electrophysiological properties and the mechanisms for the
ischemic arrhythmias [48]. The results of published reports maintenance of arrhythmias. ET-1 had no significant effect
investigating the role of ET-1 on reperfusion arrhythmias on local refractory periods, left ventricular conduction
are controversial. Some investigators demonstrated that pattern and the overall activation pattern, whereas acute
ET-1 exacerbated reperfusion injury and reperfusion ar- ischemia caused by ligation induced local conduction delay
rhythmias in rat hearts by a mechanism likely involving and prolonged refractoriness homogenously in all myocar-
1 1
activation of the Na /H exchanger [49–51]. In contrast, dial levels. Furthermore, ET-1-induced arrhythmias were
Jacobsen et al. demonstrated that reperfusion of ischemic exclusively based on focal mechanisms, whereas during
rat hearts caused arrhythmias in the presence of norepi- ligation, macroreentrant mechanisms were involved in the
nephrine or thrombin, but not ET-1 [52]. In parallel studies maintenance of tachycardias. These differences support the
from the same group, ET-1 suppressed the development of hypothesis that ET-1 may exert an intrinsic arrhythmo-
reperfusion arrhythmias initiated by either agent [53]. It genic effect. However, the investigators in both of the
was proposed that inhibition of inositol triphosphate (IP ) above-mentioned studies could not exclude the possibility3
generation was responsible as a possible mechanism. that ET-1 infusion at the doses used could cause some
However, the concept of antiarrhythmic potential of ET-1 degree of accompanying regional, if not generalized,
in these in vitro studies with global ischemia should be ischemia. In any case, a direct role for ET-1 in the
evaluated with caution. The effects of ET-1 in vivo are development of arrhythmias awaits more conclusive data,
multifactorial, including the action of cathecholamines, and this will be a difficult task in view of the agent’s
which may be absent or present only locally. Therefore, marked vasoconstrictive potency and its increased secre-
the discrepancies in the observed effects of ET-1, being tion in a complex substrate.
proarrhythmic or antiarrhythmic, are related to the differ- Although exogenous ET-1 infusion is known to cause
ent conditions studied, and points out the importance of arrhythmias under ischemic conditions and may also have
analyzing data in comparable models. a direct role in arrhythmogenesis, some studies suggest
that ET-1 may, under certain conditions, be antiarrhythmic.
Sharif et al. showed that a very low dose of ET-1, given as
3.2. Direct arrhythmogenic effects of exogenous a bolus injection prior to ischemia, may protect against
endothelin ischemic arrhythmias by mechanisms mimicking ischemic
preconditioning [56]. In this study, ET receptor antagonists
Early after the discovery of the peptide, a direct role for caused a further reduction in the number of ventricular
ET-1 in arrhythmogenesis has been investigated. Yorikane ectopic beats, and the incidence of ventricular fibrillation
et al. demonstrated, for the first time, that exogenous ET-1 and mortality. Downregulation of epsilon-subtype protein
may exhibit an arrhythmogenic action that is not solely kinase C was suggested to play a role in preconditioning of
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the coronary artery against vasoconstriction by ET-1 [57]. ers are very scarce. Raschack et al. demonstrated antiar-
However, the hypothesis that suggests a possible beneficial rhythmic and antifibrillatory effects of an ET antagonistA
role for ET-1 in ischemic preconditioning is not universal- (LU 135252, darusentan) on ischemic ventricular arrhyth-
ly accepted [58]. mias in pigs, which have large non-self defibrillating hearts
lacking relevant collateral circulation [14]. Intravenous
3.3. Endogenous endothelin: are physiological levels injection of the drug at a dose of 3 mg/kg prior to
arrhythmogenic? occlusion of the left anterior descending artery signifi-
cantly prolonged the time of regular sinus rhythm within
Endogenous release of ET-1 occurs under basal and the first 20 min of ischemia, reduced the number of
hypoxic or ischemic conditions. Under normoxic con- ventricular ectopics and the total incidence of ventricular
ditions, basal NO release results in tonic inhibition of ET-1 fibrillation. In humans, however, the clinical relevance of
production [59]. Under ischemic conditions, ET-1 forma- ET-1 activity under pathophysiological conditions of is-
tion is still subject to modulation by NO, but this remains chemia or other disease states is yet to be determined.
insufficient as compared to the increased net release and
action of ET-1. The enhanced ET-1 formation contributes
to the extension of ischemia-induced myocardial injury by
resulting in myocardial and endothelial cell death with 4. Mechanisms of endothelin-induced arrhythmias
concomitant outflow of LDH, an established marker of cell
viability, and L-arginine, the NO precursor. Three basic concepts account for the majority of ar-
Elevated plasma levels of ET-1 have been reported in rhythmias: reentry, increased automaticity and triggered
animal experimental models of ischemia [60] as well as in activity. Reentry, which gives rise to arrhythmias in most
patients with ischemic heart disease [25,61,62]. The clini- cases, may occur over a large circuit (macroreentry) or
cal relevance of ET-1 in certain clinical situations, such as may involve a small circuit (microreentry). Arrhythmias
in the maintenance of basal vascular tone and blood caused by microreentrant circuits, increased automaticity
pressure in humans, has been demonstrated by local and and triggered activity are determined to be focal in origin
systemic vasodilatation in response to ET receptor antago- in electrophysiological testing.
nists [63,64]. However, most studies on ET ar- The pathophysiological basis of ET-induced arrhythmias
rhythmogenesis studied the effects of pharmacological is not known. However, several mechanisms have been
quantities of exogenously administered ET-1. For example, proposed (Table 2). Three-dimensional mapping revealed
despite the fact that very high concentrations of ET-1 were that all tachyarrhythmias caused by exogenous administra-
shown to be present in pericardial fluid of humans [65] and tion of ET-1 were exclusively based on mono or multifocal
dogs [7], the level of exogenous ET-1 infused into the activity and there was no evidence of macroreentry.
pericardial space that induced ventricular arrhythmias was Transmembrane potential recordings using conventional
10-fold higher as compared to endogenous pericardial fluid microelectrode techniques showed that the dose-dependent
ET-1 levels under physiological conditions [66]. It remains positive inotropic response to ET-1 [68] was accompanied
to be determined whether ET-1 levels in pericardial fluid by prolongation of the cardiac action potential duration
or other body fluids can ever reach sufficiently high levels (APD) [3]. It has been suggested that early afterdepolariza-
to induce arrhythmias in different pathophysiological tions (EAD), oscillatory potentials that occur during the
conditions. On the other hand, circulating levels of ET-1, action potential plateau or during late repolarization, are
which represent only an overflow of endogenous tissue- involved in the genesis of ET-1-induced arrhythmias [3].
bound ET-1, also do not reflect a true estimate of ET-1 Similarly, a significant increase in endocardial and epicar-
activity. Although plasma levels may not be high enough dial monophasic APD90 and QT interval were reported in
to directly stimulate cardiac muscle, it is possible that several experiments [7–9]. Focal origin of arrhythmias,
locally synthesized and abluminally released ET-1 may APD prolongation and generation of EADs favor triggered
stimulate cardiac muscle [67]. activity as a likely mechanism. Permanent bradycardia
The available data showing the physiological importance induced by radiofrequency ablation of the AV node aug-
of suppressing endogenous ET-1 using ET receptor block- mented the direct proarrhythmic effect of ET-1 in dogs
Table 2
aMechanisms of action by which ET-1 may promote the development of arrhythmias
Arrhythmogenic mechanism Molecular changes
21Triggered activity Early afterdepolarizations Ca mobilization (generation of IP )3
1APD prolongation fl K currents (inhibition of I )K
Microreentry (?) Increased dispersion of APD
Regional heterogeneity
a 1APD, action potential duration; IP , inositol triphosphate. I , delayed rectifier K current.3 K
F. Duru et al. / Cardiovascular Research 49 (2001) 272 –280 277
[10], supporting the hypothesis that triggered activity may may be responsible for the APD prolongation, especially in
be operative. Also compatible with this hypothesis, induc- the presence of b-adrenergic stimulation [76]. The disper-
tion rates with programmed ventricular stimulation were sion of APD, which has been observed in some animal
low [8]. On the other hand, regional heterogeneity in the studies, may be caused by an altered balance between the
electrophysiological effects of ET-1 and increased AP inward and outward ion channels that are modulated by
dispersion [9] may favor microreentry, a mechanism which ET-1. In addition, as early pioneering work by Coraboeuf
could not be ruled out in three-dimensional mapping [55]. showed, acidosis that occurs during ischemia induces a
1decrease in K conductance that can be responsible for
ectopic foci causing arrhythmias by the mechanism of
4.1. Ion channels EADs [77]. ET-1 is also a mediator of the activation of the
1 1
cardiac sarcolemmal Na /H exchanger, which is causal-
ET-1 has been shown to regulate cardiac function ly linked with acidosis, while inhibition of the exchanger is
21through the modulation of ion channels. The role of Ca known to be associated with a decreased susceptibility to
channels in ET-1 arrhythmogenesis was investigated by severe ventricular arrhythmias [78,79]. In guinea pig
Solti et al. [11] ET-1 was administered into the left anterior papillary muscles in vitro, ET antagonism prevented
descending artery of 24 open-chest dogs. Twelve dogs hypoxia-induced impairment of intercellular coupling [14].
21
received the Ca -channel blocker verapamil before ET-1 Therefore, it was speculated that the antiarrhythmic effects
administration and twelve animals served as controls. may be secondary to a direct cellular antihypoxic action.
Electrophysiological studies were performed by pro- Apart from the above-mentioned possible mechanisms, ET
grammed electrical stimulation of the heart. In the control receptor blockade may reduce cellular injury, an effect that
group, sustained ventricular tachycardia and ventricular may be antiarrhythmic independent of any effect on ion
fibrillation developed in nine dogs, whereas in the ver- channels and repolarization.
apamil-pretreated group, arrhythmias occurred only in two
21
animals. This study may suggest that Ca ion channels
may be involved in the arrhythmogenic action of ET-1. It
may be argued, however, that elimination of ventricular 5. Therapeutic potential of endothelin-antagonists
21
arrhythmias by Ca -channel blockade could result from
the antagonizing vasoconstrictive effects of ET-1 [69,70]. ET receptor blockade has been shown to have a thera-
ET-1-induced vascular contraction is accompanied by an peutic potential in experimental and early clinical studies
21increase in intracellular Ca , which consists of two in hypertension, atherosclerosis, heart failure, pulmonary
21phases: (a) an initial transient rapid Ca release is the disease, and renal end-organ damage [28,80]. The recent
21
result of mobilization of Ca from intracellular stores and observation of the potential arrhythmogenic effects of
21(b) a sustained phase, which is dependent on external Ca ET-1 in animal studies has resulted in growing interest to
21
and is the result of transmembrane Ca influx [71]. It has investigate the antiarrhythmic potential of ET antagonists.
21been proposed that ET-1 mobilizes Ca from the sarcop-
lasmic reticulum store via IP , because generation of IP3 3
accompanies ET-1 stimulation of smooth muscle cells 5.1. Which receptors are involved in endothelin
[72]. Previous studies have implicated this water-soluble arrhythmogenesis?
cytoplasmic second messenger in the genesis of arrhyth-
mias under ischemic and reperfusion conditions [73–75]. Ventricular arrhythmias induced by ET-1 are most likely
However, molecules other than IP may also mediate the to be suppressed by ET receptor antagonists. Garjani et3 A
21ET-induced Ca release from intracellular stores [71]. al. showed that the ET receptor antagonist BQ-123A
Concerning the nature of the ion channel through which completely abolished the ventricular proarrhythmic effects
21transmembrane Ca influx occurs, it was originally of exogenous ET-1 during acute myocardial ischemia in
postulated that ET-1 was an endogenous ligand at voltage- anesthetized rats [12]. The antiarrhythmic potential of
21dependent L-type Ca channels [18]. The EADs induced another ET receptor antagonist, BQ-485, was investigatedA
by ET-1 were abolished by nicardipine, supporting the in a study by Ercan et al. which showed complete blockade
hypothesis that L-type currents (I ) were involved in the of the arrhythmogenic effects of ET-1 [13]. In BQ-485Ca,L
genesis of EADs [3]. However, several studies reported pretreated rat hearts, ET-1 caused a fall in coronary
contradictory observations showing no or only marginal perfusion pressure and a slight positive inotropic response.
21
effect of the same Ca antagonists on ET-1-induced BQ-485 at the same concentration also caused a significant
vasoconstriction [71]. reduction in the duration of ventricular arrhythmias in the
21 1In addition to Ca influx, K currents may also be guinea pig isolated perfused heart. ET antagonists BQ-A
involved for the observed electrophysiologic effects. The 123 and A-127722 significantly reduced the arrhythmo-
1delayed rectifier K current is important in the repolariza- genic effects of pulmonary big ET-1, which is converted
tion of the cardiac action potential. It has been shown that into ET-1 during coronary passage, in a model of serial
1ET-1-induced inhibition of delayed rectifier K current lung–heart perfusion in both control and atherosclerotic
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rabbits [81]. Similarly, another ET antagonist LU 135252 eral recent animal studies suggesting that ET antagonistsA
reduced arrhythmic events in ischemic pigs [14]. may have antiarrhythmic properties. Development of
Nonselective ET-1 receptor antagonists also may inhibit myocardial ischemia is a likely mechanism for the ar-
the arrhythmogenic actions of ET-1. Bosentan has been rhythmogenic effects of ET-1. A direct arrhythmogenic
shown to effectively suppress intrapericardial ET-induced action that is not related to myocardial ischemia has also
ventricular arrhythmias in dogs [82]. Likewise, intracoron- been proposed, but this topic remains to be elucidated.
ary administration of SB 209670 inhibited the arrhythmo- Whilst the available data is preclinical and cannot be easily
genic actions of ET-1 [83]. Another non-selective agent, extrapolated to human disease states, this is an interesting
TAK-044, significantly reduced reperfusion arrhythmias in area of research. Clinical conditions such as ischemic
rat hearts [84]. However, the role of ET receptors syndromes and congestive heart failure are associated withB
contributing to arrhythmias remains controversial. In a a high risk of sudden death, believed in most cases
study by Alexiou et al., ET antagonists (BQ-123 and secondary to ventricular tachyarrhythmias. Under suchA
A-127722) partly suppressed the arrhythmias induced by pathophysiological conditions, endogenous ET-1 might
ET-1, whereas ET antagonists (IRL-1038 and IRL-1025) play an important role in the complex and multifactorialB
had no effect [81]. In contrast, Sharif et al., demonstrated milieu of arrhythmogenesis. In this respect, the role of ET
that the ET antagonist PD 161721 suppressed the number antagonists as potential antiarrhythmic agents, besides theirB
of ventricular ectopic beats, decreased the incidence of other beneficial effects, may be of great clinical relevance.
ventricular arrhythmias and mortality in rats after coronary Controlled clinical studies are needed to investigate the
artery occlusion [56]. effects of physiologically relevant concentrations of ET-1
on arrhythmogenesis and to determine whether ET antago-
nists have potential antiarrhythmic effects in humans.
6. Differential effects of endothelin in atria and
ventricles
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